Recombinant Human Anti-CTLA4 x Human Anti-GLUT2 Bispecific Antibody (scFv-CH1/CL) (BSCC-H314)

Recombinant Anti-CTLA4 x Anti-GLUT2 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CTLA4 antibody variable domain is fused to CH1 and the other scFv from an anti-GLUT2 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can bind two factors simultaneously. It is designed for the research of Renal cell cancer (RCC) therapy.

Datasheet INQUIRY

Specifications

Targets

CTLA4 & GLUT2

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Renal cell cancer (RCC)

Targets

Target 1

CTLA4

Gene ID

1493

UniProt ID

P16410

Alternative Names

CTLA4; cytotoxic T-lymphocyte-associated protein 4; CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3; cytotoxic T-lymphocyte protein 4; CD152 isoform; celiac disease 3; insulin-dependent diabetes mellitus 12; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4

Target 2

GLUT2

Gene ID

6514

UniProt ID

P11168

Alternative Names

SLC2A2; solute carrier family 2 (facilitated glucose transporter), member 2; GLUT2; solute carrier family 2, facilitated glucose transporter member 2; glucose transporter type 2, liver

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CTLA4 x Human Anti-GLUT2 Bispecific Antibody (scFv-CH1/CL) (BSCC-H314). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CTLA4 x Human Anti-GLUT2 Bispecific Antibody (scFv-CH1/CL) (CAT#: BSCC-H314)

Specifications

Targets

Customer Reviews and Q&As